Literature DB >> 35972693

PD-1, PD-L1 and cAMP immunohistochemical expressions are associated with worse oncological outcome in patients with bladder cancer.

Giorgio Ivan Russo1, Nicolò Musso2,3, Arturo Lo Giudice4,5, Maria Giovanna Asmundo4, Marina Di Mauro4, Paolo G Bonacci2, Mariacristina Massimino2, Dalida Bivona2, Stefania Stefani2, Elisabetta Pricoco6, Matteo Ferro5, Massimo Camarda3, Sebastiano Cimino4, Giuseppe Morgia4,7, Rosario Caltabiano6, Giuseppe Broggi6.   

Abstract

PURPOSE: In this study, we aimed to identify prognostic factors of cancer mortality in patients who received radical cystectomy and to identify genomic alterations in a sub-cohort of patients with locally advanced (pT3-4) and/or positive lymph nodes bladder cancer (BC).
METHODS: We collected 101 BC samples from 2010 to 2018 who previously received radical cystectomy. Immunohistochemical slides were evaluated for PPAR, cAMP, IMP3, Ki67, CDK4, POU5F1, Cyclin E and MDM2, p65, CD3, CD4, CD8, CD20, CD68, CD163, FOXP3, PD-1 and PD-L1 expression. We calculated a prognostic score (PS) based on the positivity to PD-1, PD-L1 and of cAMP (final score ranging from 0 to 3). DNA of each sample have been used for sequencing by NGS in a sub-cohort of 6 patients with locally advanced (pT3-4) and/or positive lymph nodes BC.
RESULTS: PD-1 + (HR [hazard ratio] 2.59; p = 0.04), PD-L1+ (HR = 6.46; p < 0.01) and cAMP+ (HR 3.04; p = 0.02) were independent predictors of cancer-specific mortality (CSM). Increase of PS (score = 0 as reference) was associated with CSM, 0.81 (p = 0.80), 4.72 (p = 0.01) and 10.51 (p < 0.0) for PS 1, 2 and 3, respectively. ERBB2 was the gene most frequently mutated.
CONCLUSION: BC exhibited heterogenous protein expression and variable genomic features. Identification of expression of PD-1, PD-L1 and cAMP could help in predicting oncological outcomes.
© 2022. The Author(s).

Entities:  

Keywords:  Bladder cancer; Genes; Immunotherapy; NGS; PD-1; Tumor-infiltrating lymphocytes

Year:  2022        PMID: 35972693     DOI: 10.1007/s00432-022-04262-0

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.322


  21 in total

1.  Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.

Authors:  Joaquim Bellmunt; Maha Hussain; Jürgen E Gschwend; Peter Albers; Stephane Oudard; Daniel Castellano; Siamak Daneshmand; Hiroyuki Nishiyama; Martin Majchrowicz; Viraj Degaonkar; Yi Shi; Sanjeev Mariathasan; Petros Grivas; Alexandra Drakaki; Peter H O'Donnell; Jonathan E Rosenberg; Daniel M Geynisman; Daniel P Petrylak; Jean Hoffman-Censits; Jens Bedke; Arash Rezazadeh Kalebasty; Yousef Zakharia; Michiel S van der Heijden; Cora N Sternberg; Nicole N Davarpanah; Thomas Powles
Journal:  Lancet Oncol       Date:  2021-03-12       Impact factor: 41.316

2.  Cell and tissue microarray technologies for protein and nucleic acid expression profiling.

Authors:  Marina Cardano; Giuseppe R Diaferia; Maurizio Falavigna; Chiara C Spinelli; Fausto Sessa; Pasquale DeBlasio; Ida Biunno
Journal:  J Histochem Cytochem       Date:  2012-11-19       Impact factor: 2.479

Review 3.  The immune contexture in human tumours: impact on clinical outcome.

Authors:  Wolf Herman Fridman; Franck Pagès; Catherine Sautès-Fridman; Jérôme Galon
Journal:  Nat Rev Cancer       Date:  2012-03-15       Impact factor: 60.716

Review 4.  TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy.

Authors:  Yemsratch T Akalu; Carla V Rothlin; Sourav Ghosh
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

Review 5.  Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group.

Authors:  Ashish M Kamat; Richard J Sylvester; Andreas Böhle; Joan Palou; Donald L Lamm; Maurizio Brausi; Mark Soloway; Raj Persad; Roger Buckley; Marc Colombel; J Alfred Witjes
Journal:  J Clin Oncol       Date:  2016-01-25       Impact factor: 44.544

6.  Intravesical Anti-PD-1 Immune Checkpoint Inhibition Treats Urothelial Bladder Cancer in a Mouse Model.

Authors:  Austin N Kirschner; Jian Wang; Anne Rajkumar-Calkins; Kevin E Neuzil; Sam S Chang
Journal:  J Urol       Date:  2020-12-24       Impact factor: 7.600

7.  LINC00483 Has a Potential Tumor-Suppressor Role in Colorectal Cancer Through Multiple Molecular Axes.

Authors:  Duilia Brex; Cristina Barbagallo; Federica Mirabella; Angela Caponnetto; Rosalia Battaglia; Davide Barbagallo; Rosario Caltabiano; Giuseppe Broggi; Lorenzo Memeo; Cinzia Di Pietro; Michele Purrello; Marco Ragusa
Journal:  Front Oncol       Date:  2021-01-20       Impact factor: 6.244

8.  Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.

Authors:  Dean F Bajorin; J Alfred Witjes; Jürgen E Gschwend; Michael Schenker; Begoña P Valderrama; Yoshihiko Tomita; Aristotelis Bamias; Thierry Lebret; Shahrokh F Shariat; Se Hoon Park; Dingwei Ye; Mads Agerbaek; Deborah Enting; Ray McDermott; Pablo Gajate; Avivit Peer; Matthew I Milowsky; Alexander Nosov; João Neif Antonio; Krzysztof Tupikowski; Laurence Toms; Bruce S Fischer; Anila Qureshi; Sandra Collette; Keziban Unsal-Kacmaz; Edward Broughton; Dimitrios Zardavas; Henry B Koon; Matthew D Galsky
Journal:  N Engl J Med       Date:  2021-06-03       Impact factor: 91.245

9.  Prognostic impact of tumor infiltrating lymphocytes on patients with metastatic urothelial carcinoma receiving platinum based chemotherapy.

Authors:  Hui-Shan Huang; Harvey Yu-Li Su; Pei-Hsu Li; Po-Hui Chiang; Cheng-Hua Huang; Chien-Hsu Chen; Meng-Che Hsieh
Journal:  Sci Rep       Date:  2018-05-10       Impact factor: 4.379

10.  SRSF-1 and microvessel density immunohistochemical analysis by semi-automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study).

Authors:  Giuseppe Broggi; Arturo Lo Giudice; Marina Di Mauro; Maria Giovanna Asmundo; Elisabetta Pricoco; Eliana Piombino; Rosario Caltabiano; Giuseppe Morgia; Giorgio Ivan Russo
Journal:  Prostate       Date:  2021-07-01       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.